Scientists test new strategy to keep advanced breast cancer in check
NCT ID NCT02738866
Summary
This study is testing whether continuing the drug palbociclib, but pairing it with a different hormone therapy called fulvestrant, can help control metastatic breast cancer that has started growing again after initial treatment. It will involve about 60 people whose cancer progressed while on palbociclib and another type of hormone drug. The main goal is to see how long this new combination can keep the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Health Network (AHN) - Allegheny General Hospital ONLY
Pittsburgh, Pennsylvania, 15212, United States
-
Anne Arundel Health System Research Institute, Inc.
Annapolis, Maryland, 21401, United States
-
Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016, United States
-
Reading Hospital - McGlinn Cancer Institute
West Reading, Pennsylvania, 19611, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.